150 related articles for article (PubMed ID: 38443329)
21. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori.
Li M; Oshima T; Horikawa T; Tozawa K; Tomita T; Fukui H; Watari J; Miwa H
Helicobacter; 2018 Aug; 23(4):e12495. PubMed ID: 29873436
[TBL] [Abstract][Full Text] [Related]
22. The Efficacy and Safety of Regimens for Helicobacter pylori Eradication Treatment in China: A Systemic Review and Network Meta-Analysis.
Li J; Shi H; Zhou F; Xie L; Lin R
J Clin Gastroenterol; 2024 Jan; 58(1):12-23. PubMed ID: 38084866
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
Zhang WL; Lin BS; Li YY; Ding YM; Han ZX; Ji R
Digestion; 2023; 104(4):249-261. PubMed ID: 37015201
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States.
Yunusa I; Love BL
Am J Gastroenterol; 2023 Apr; 118(4):635-644. PubMed ID: 36693030
[TBL] [Abstract][Full Text] [Related]
25. Efficacy comparison of 7- and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial.
Oh CK; Lim H; Seo SI; Lee SP; Bang CS; Shin WG; Kim JB; Jang HJ; Baik GH
BMC Gastroenterol; 2023 Dec; 23(1):453. PubMed ID: 38129806
[TBL] [Abstract][Full Text] [Related]
26. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
Luther J; Higgins PD; Schoenfeld PS; Moayyedi P; Vakil N; Chey WD
Am J Gastroenterol; 2010 Jan; 105(1):65-73. PubMed ID: 19755966
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis.
Shinozaki S; Kobayashi Y; Osawa H; Sakamoto H; Hayashi Y; Lefor AK; Yamamoto H
Digestion; 2021; 102(3):319-325. PubMed ID: 31914442
[TBL] [Abstract][Full Text] [Related]
28. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the Efficacy of Two-Week Vonoprazan Versus Lansoprazole-Based Quadruple Sequential Antibiotic Therapy in Eradicating Helicobacter pylori Infection: A Non-randomized Clinical Trial.
Nizam A; Chaudary ZI; Ahmad SA; Nawaz N; Riaz Z; Shehzad A; Jamil MI
Cureus; 2024 Jan; 16(1):e52758. PubMed ID: 38389593
[TBL] [Abstract][Full Text] [Related]
30. Colloidal bismuth pectin-containing quadruple therapy as the first-line treatment of Helicobacter pylori infection: A multicenter, randomized, double-blind, non-inferiority clinical trial.
Xie Y; Hu Y; Zhu Y; Wang H; Wang QZ; Li YQ; Wang JB; Zhang ZY; Zhang DK; Liu XW; Lu NH
Helicobacter; 2023 Jun; 28(3):e12978. PubMed ID: 37002653
[TBL] [Abstract][Full Text] [Related]
31. Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial.
Liu DN; Wang QY; Li PY; Wu DH; Pan J; Chen ZY; Li YQ; Han XY; Lan C; Tang J; Tan Y; Mo CY; Yang WZ; Han JL; Huang XX
Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102125. PubMed ID: 37062356
[TBL] [Abstract][Full Text] [Related]
32. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
Jung YS; Kim EH; Park CH
Aliment Pharmacol Ther; 2017 Jul; 46(2):106-114. PubMed ID: 28497487
[TBL] [Abstract][Full Text] [Related]
33. [Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of
Zhang M; Chen CY; Wang XT; Lyu B
Zhonghua Nei Ke Za Zhi; 2017 May; 56(5):368-374. PubMed ID: 28460509
[No Abstract] [Full Text] [Related]
34. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.
Hsu PI; Tsai FW; Kao SS; Hsu WH; Cheng JS; Peng NJ; Tsai KW; Hu HM; Wang YK; Chuah SK; Chen A; Wu DC
Am J Gastroenterol; 2017 Sep; 112(9):1374-1381. PubMed ID: 28719592
[TBL] [Abstract][Full Text] [Related]
35. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
He XJ; Wang XL; Huang XY; Li DZ; Liu G; Wang W; Li DL
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102052. PubMed ID: 36400418
[TBL] [Abstract][Full Text] [Related]
36. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial.
Guan JL; Hu YL; An P; He Q; Long H; Zhou L; Chen ZF; Xiong JG; Wu SS; Ding XW; Luo HS; Li PY
Pharmacotherapy; 2022 Mar; 42(3):224-232. PubMed ID: 35075679
[TBL] [Abstract][Full Text] [Related]
37. Research trends on vonoprazan-based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023.
Du RC; Ouyang YB; Lu NH; Hu Y
Helicobacter; 2023 Oct; 28(5):e13012. PubMed ID: 37515414
[TBL] [Abstract][Full Text] [Related]
38. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
Furuta T; Yamade M; Kagami T; Uotani T; Suzuki T; Higuchi T; Tani S; Hamaya Y; Iwaizumi M; Miyajima H; Umemura K; Osawa S; Sugimoto K
Digestion; 2020; 101(6):743-751. PubMed ID: 31434101
[TBL] [Abstract][Full Text] [Related]
39. Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.
Hou X; Meng F; Wang J; Sha W; Chiu CT; Chung WC; Gu L; Kudou K; Chong CF; Zhang S
J Gastroenterol Hepatol; 2022 Jul; 37(7):1275-1283. PubMed ID: 35342997
[TBL] [Abstract][Full Text] [Related]
40. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.
Li Y; Huang X; Yao L; Shi R; Zhang G
Wien Klin Wochenschr; 2010 Jul; 122(13-14):413-22. PubMed ID: 20628905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
